Rep. Lisa C. McClain Sells Globus Medical, Inc. (NYSE:GMED) Stock

Key Points

• Representative Lisa C. McClain sold between $1,001 and $15,000 in Globus Medical, Inc. (NYSE:GMED) stock on June 24th, according to a filing disclosed on August 13th.
• Globus Medical reported a quarterly revenue increase of 18.4% year-over-year, with an EPS of $0.86, surpassing analyst expectations of $0.76.
• The Board of Globus Medical has approved a $500 million share repurchase program, indicating confidence in the stock's value.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Globus Medical, Inc. NYSE: GMED. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Globus Medical stock on June 24th.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Globus Medical Stock Up 1.0%

GMED stock opened at $60.63 on Friday. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $94.93. The firm has a market cap of $8.21 billion, a P/E ratio of 23.32, a P/E/G ratio of 1.68 and a beta of 1.20. The company's 50-day moving average price is $57.22 and its two-hundred day moving average price is $67.33.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Thursday, August 7th. The medical device company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.76 by $0.10. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. The firm had revenue of $745.34 million for the quarter, compared to analyst estimates of $738.91 million. During the same period last year, the firm earned $0.75 EPS. The business's quarterly revenue was up 18.4% compared to the same quarter last year. Equities analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current year.

Globus Medical declared that its board has approved a share repurchase program on Thursday, May 15th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the medical device company to repurchase up to 6.3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board believes its shares are undervalued.

Analysts Set New Price Targets

Several research firms have commented on GMED. Barclays reissued an "overweight" rating on shares of Globus Medical in a report on Tuesday, June 10th. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a report on Tuesday, May 27th. Needham & Company LLC reissued a "hold" rating on shares of Globus Medical in a report on Monday, July 21st. Wall Street Zen raised shares of Globus Medical from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Piper Sandler reduced their price target on shares of Globus Medical from $100.00 to $80.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Globus Medical currently has an average rating of "Moderate Buy" and an average price target of $87.64.

Institutional Investors Weigh In On Globus Medical

Several hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its position in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock worth $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of Globus Medical in the 2nd quarter worth approximately $28,000. Farther Finance Advisors LLC lifted its position in shares of Globus Medical by 145.5% in the 1st quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company's stock worth $30,000 after purchasing an additional 240 shares during the period. Larson Financial Group LLC lifted its position in shares of Globus Medical by 1,007.7% in the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company's stock worth $32,000 after purchasing an additional 393 shares during the period. Finally, Parallel Advisors LLC lifted its position in shares of Globus Medical by 62.1% in the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company's stock worth $37,000 after purchasing an additional 193 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.